SDS Optic optical coatings subpage

Investor relations

Company profile

SDS Optic S.A. develops innovative products for medical diagnostics. The flagship project of SDS Optic S.A. is inPROBE, a fiber-optic microsensor for oncology diagnostics.

SDS Optic calendar for periodic reports in 2025

Investor's calendar

Schedule of periodic report publications in 2025:

Quarterly report for Q4 2024 – February 14, 2025

Quarterly report for Q1-2025 – May 15, 2025

Quarterly report for Q2-2025 – August 14, 2025

Quarterly report for Q3-2025 – November 14, 2025

Annual report for 2024 – May 28, 2025

IR

Contact for investors

Karol Maryniowski

Marketing, Communications and IR Manager

+48 81 501 94 63ir@sdsoptic.comFrequently asked questions

Stock quote

The company has been listed on the NewConnect market of the Warsaw Stock Exchange since March 15, 2022

Sector: medical equipment and supplies

ISIN: PLSDSO00013

Ticker: SDS

Learn more
SDS Optic shareholder structure

Shareholder structure

based on the information held by the Company as of the date of publication of the most recent periodic report.

SDS Optic shareholders structure
View each share series

SDS Optonic Sp. z o.o. is a subsidiary of Mr. Marcin Staniszewski, CEO of SDS Optic S.A., who, together with his spouse and the financial shareholders of SDS Optonic Sp. z o.o., as at the date of publication of this report, jointly hold 2,498,160 shares in the Company, representing 42.10% of the Company’s share capital. These shares entitle the holders to exercise 2,498,160 votes at the General Meeting of the Issuer, corresponding to 42.10% of the total voting rights in the Company. Pursuant to the provisions of the shareholders’ agreement of SDS Optonic sp. z o.o., concluded on 18 June 2021 and described in Current Report ESPI No. 3/2022 dated 16 February 2022, Mr. Marcin Staniszewski is entitled to a total of 1,234,935 shares in the Issuer, representing 20.81% of the Company’s share capital, while the remaining shareholders of SDS Optonic sp. z o.o. are entitled to 1,147,825 shares in the Issuer, representing 19.35% of the Company’s share capital.

SDS Optic group Structure

SDS Optic Group Capital Structure

As of the end of December 2024, SDS Optic S.A. is the parent company of two subsidiaries, FiBioMed Sp. z o.o. and SDS Optic Inc., in which it holds majority stakes

FiBioMed Sp. z o.o.– a company established to work on the development of fiber optic technologies in the field of infectious diseases. These activities are carried out based on a license agreement signed with SDS Optic S.A. SDS Optic S.A. holds 579 shares in FiBioMed Sp. z o.o. with a nominal value of PLN 28,950.00, representing 82.7% of the company’s share capital.

SDS Optic Inc. (USA) is an R&D center in Philadelphia, established to develop technologies in the field of cancer marker and eye disease diagnostics by creating biological components of the technology. SDS Optic S.A. holds 100% of the share capital of SDS Optic Inc.

Authorized Advisor and Market Animator

Authorized Advisor

Navigator logo

Navigator Capital S.A.

18 Twarda Street, Warsawbiuro@navigatorcapital.plhttps://navigatorcapital.pl/+48 22 630 83 33

Market Animator

Navigator logo

DM BOŚ

78/80 Marszałkowska St, Warsawmakler@bossa.plhttps://bossa.pl/+48 22 504 31 04

We Care About Your Privacy

SDS Optic S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.